{
  "docId": "019de070-699f-77f8-bbbb-b770da56fde3",
  "docSlug": "068a25e0403b2abb3acbdc102f073cd6",
  "documentTitle": "BioNTech | Results Presentation Deck | 25 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 25,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/4",
  "deckHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3",
  "deckJsonHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json",
  "deckAnchorHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.92,
        "x": 0.04,
        "y": 0.195
      },
      "kind": "list",
      "text": "BNT 162 COVID-19 Vaccine Program: Achieved Success in First Interim Analysis from Phase 3 Study; No serious adverse events; Rolling submissions ongoing; On track for EUA; Initiated trials in Japan/China; Acquired GMP facility; Commercial planning underway.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f9493ab-1440-44b2-9547-d79e3876c736",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.76
      },
      "kind": "list",
      "text": "Financial Update and Outlook: Closed $1.2B financing; $0.8B net cash receipts; $1.2B cash position.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a2f30ca-d8a5-469e-996f-f21c6ca964ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Oncology Pipeline: Promising early Phase 1 data for BNT311; Early Phase 1 data for BNT131 and BNT114; IND approval for iNeST (BNT122); First patient dosed in BNT411.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0510f5d-6db8-4864-88ba-328bd10bc1a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.73,
        "x": 0.09,
        "y": 0.935
      },
      "kind": "source-note",
      "text": "Amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f52a185b-e04e-4e0a-bc58-c55b5b6614ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.265,
        "x": 0.038,
        "y": 0.095
      },
      "kind": "title",
      "text": "Q3 2020 Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed00d7ff-e75b-4c39-8a36-aaef172d9e4c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e8802553-2fcd-4e5e-b1e4-8ed7fad83003",
      "evidence": "list/bullet: BNT 162 COVID-19 Vaccine Program: Achieved Success in First Interim Analysis from Phase 3 Study; No serious adverse events; Rolling submissions ongoing; On track for EUA; Initiated trials in Japan/China; Acq",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "cbfce4db-5b7b-4c8f-806a-40f9ab62d11e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "Q3 2020 Highlights",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}